This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
{{decree|type=notice|message=This article is in the 'Talk' namespace because it is an unfinished draft. This section is used to host drafts for unpublished articles as well as discussions for published ones. If you'd like to use this area to discuss this draft, please do so in the 'Discussion' section at the very bottom of the page. This notice will be removed once this draft has been approved for publication by an administrator.}}
{{headerpanel|{{Approval}}}}
{{headerpanel|{{Approval}}}}
{{SummarySheet}}
{{SummarySheet}}
Glaucine is a naturally occurring novel [[psychedelic]] substance of the [[aporphine]] class found in ''[[Glaucium Flavum]]''.<ref>https://link.springer.com/article/10.1023/B:PHAC.0000048907.58847.c6</ref> Glaucine has one stereocenter, therefore it has two stereoisomers, where (S)-Glaucine is a 5-HT<sub>2A</sub> [[agonist]] and (R)-Glaucine is a 5-HT<sub>2</sub> positive allosteric modulator.<ref name=":1">https://onlinelibrary.wiley.com/doi/10.1111/cbdd.13390</ref> Its psychedelic effects are believed to be produced by its interaction with [[serotonin]] [[Receptor|receptors]] like most psychedelics do, but also has clinically significant interactions at D1<ref>https://www.sciencedirect.com/science/article/abs/pii/S0968089605002312?via%3Dihub</ref> and α1<ref name=":2">https://pubmed.ncbi.nlm.nih.gov/30216681/</ref> receptors as an [[antagonist]], and inhibits MOA to a moderate degree.<ref>https://www.sciencedirect.com/science/article/abs/pii/S0021967319301104?via%3Dihub</ref> Glaucine has a close relative found in [[Blue Lotus]] (''Nymphaea nouchali)'' called [[apomorphine]]. It is both psychedelic as well as sedating, but the [[sedation]] is more similar to that of [[opioids]] than [[Psilocybin mushrooms|psilocybin]], a generally sedating psychedelic. It is most commonly consumed [[Routes of administration|orally]].
Glaucine is a naturally occurring novel [[psychedelic]] substance of the [[aporphine]] class found in ''[[Glaucium Flavum]]''.<ref>https://link.springer.com/article/10.1023/B:PHAC.0000048907.58847.c6</ref> Glaucine has one stereocenter, therefore it has two stereoisomers, where (S)-Glaucine is a 5-HT<sub>2A</sub> [[agonist]] and (R)-Glaucine is a 5-HT<sub>2</sub> positive allosteric modulator.<ref name=":1">https://onlinelibrary.wiley.com/doi/10.1111/cbdd.13390</ref> Its psychedelic effects are believed to be produced by its interaction with [[serotonin]] [[Receptor|receptors]] like most psychedelics do, but also has clinically significant interactions at D1<ref>https://www.sciencedirect.com/science/article/abs/pii/S0968089605002312?via%3Dihub</ref> and α1<ref name=":2">https://pubmed.ncbi.nlm.nih.gov/30216681/</ref> receptors as an [[antagonist]], and inhibits MOA to a moderate degree.<ref>https://www.sciencedirect.com/science/article/abs/pii/S0021967319301104?via%3Dihub</ref> Glaucine has a close relative found in [[Blue Lotus]] (''Nymphaea nouchali)'' called [[apomorphine]]. It is both psychedelic as well as sedating, but the [[sedation]] is more similar to that of [[opioids]] than [[Psilocybin mushrooms|psilocybin]], a generally sedating psychedelic. It is most commonly consumed [[Routes of administration|orally]].
{{SubstanceBox
{{SubstanceBox/Glaucine}}
<!-- Special Parameters -->
|displayClasses={{{displayClasses|}}}
|MaterialTable_MaxWidth=250px
|MaterialTable_Title={{PAGENAME}}
<!-- Modules -->
|ModuleSource=false
|ModuleCombination=false
|ModuleStructure=true
|ModuleNomenclature=true
|ModuleClassMembership=true
|ModuleROA=true
<!-- Source -->
|PhotoImageFile=
|PhotoImageWidth=
|PhotoImageCaption=
<!-- Combination -->
|CombinationImage1_Caption=
|CombinationImage1_File=
|CombinationImage1_Width=
|CombinationImage2_Caption=
|CombinationImage2_File=
|CombinationImage2_Width=
|CombinationImage3_Caption=
|CombinationImage3_File=
|CombinationImage3_Width=
<!-- Structure -->
|MolecularStructureCaption=Molecular structure of glaucine
|InsufflatedROA_Light=[[Insufflated min light dose::5]] - [[Insufflated max light dose::15]] mg
|InsufflatedROA_Common=[[Insufflated min common dose::15]] - [[Insufflated max common dose::40]] mg
|InsufflatedROA_Strong=[[Insufflated min strong dose::40]] - [[Insufflated max strong dose::80]] mg
|InsufflatedROA_Heavy=[[Insufflated heavy dose::80]] mg +
|InsufflatedROA_TimelineFile=
|InsufflatedROA_TimelineWidth=
|InsufflatedROA_Duration=[[Insufflated min total time::2]] - [[Insufflated max total time::4]] [[Insufflated total time units::hours]]
|InsufflatedROA_Onset=[[Insufflated min onset time::10]] - [[Insufflated max onset time::15]] [[Insufflated onset time units::minutes]]
|InsufflatedROA_Comeup=
|InsufflatedROA_Peak=[[Insufflated min peak time::1]] - [[Insufflated max peak time::1.5]] [[Insufflated peak time units::hours]]
|InsufflatedROA_Offset=[[Insufflated min offset time::1]] - [[Insufflated max offset time::2]] [[Insufflated offset time units::hours]]
|InsufflatedROA_Aftereffects=[[Insufflated min afterglow time::1]] - [[Insufflated max afterglow time::1.5]] [[Insufflated afterglow time units::hours]]
|RectalROA=false
|RectalROA_Collapsed=True
|RectalROA_Caption=
|RectalROA_Bioavailability=[[Rectal min bioavailability::x]]% - [[Rectal max bioavailability::y]]
|SubcutaneousROA_Light=[[Subcutaneous min light dose::x]] - [[Subcutaneous max light dose::y]] mg
|SubcutaneousROA_Common=[[Subcutaneous min common dose::x]] - [[Subcutaneous max common dose::y]] mg
|SubcutaneousROA_Strong=[[Subcutaneous min strong dose::x]] - [[Subcutaneous max strong dose::y]] mg
|SubcutaneousROA_Heavy=[[Subcutaneous heavy dose::x]] mg +
|SubcutaneousROA_TimelineFile=
|SubcutaneousROA_TimelineWidth=
|SubcutaneousROA_Duration=[[Subcutaneous min total time::x]] - [[Subcutaneous max total time::y]] [[Subcutaneous total time units::hours]]
|SubcutaneousROA_Onset=[[Subcutaneous min onset time::x]] - [[Subcutaneous max onset time::y]] [[Subcutaneous onset time units::minutes]]
|SubcutaneousROA_Comeup=[[Subcutaneous min comeup time::x]] - [[Subcutaneous max comeup time::y]] [[Subcutaneous comeup time units::minutes]]
|SubcutaneousROA_Peak=[[Subcutaneous min peak time::x]] - [[Subcutaneous max peak time::y]] [[Subcutaneous peak time units::hours]]
|SubcutaneousROA_Offset=[[Subcutaneous min offset time::x]] - [[Subcutaneous max offset time::y]] [[Subcutaneous offset time units::hours]]
|SubcutaneousROA_Aftereffects=[[Subcutaneous min afterglow time::x]] - [[Subcutaneous max afterglow time::y]] [[Subcutaneous afterglow time units::hours]]
|IntramuscularROA=false
|IntramuscularROA_Collapsed=true
|IntramuscularROA_Caption=
|IntramuscularROA_Bioavailability=[[Intramuscular min bioavailability::x]]% - [[Intramuscular max bioavailability::y]]%<ref>APA formatted citation</ref>
|IntramuscularROA_Light=[[Intramuscular min light dose::x]] - [[Intramuscular max light dose::y]] mg
|IntramuscularROA_Common=[[Intramuscular min common dose::x]] - [[Intramuscular max common dose::y]] mg
|IntramuscularROA_Strong=[[Intramuscular min strong dose::x]] - [[Intramuscular max strong dose::y]] mg
|IntramuscularROA_Heavy=[[Intramuscular heavy dose::x]] mg +
|IntramuscularROA_TimelineFile=
|IntramuscularROA_TimelineWidth=
|IntramuscularROA_Duration=[[Intramuscular min total time::x]] - [[Intramuscular max total time::y]] [[Intramuscular total time units::hours]]
|IntramuscularROA_Onset=[[Intramuscular min onset time::x]] - [[Intramuscular max onset time::y]] [[Intramuscular onset time units::minutes]]
|IntramuscularROA_Comeup=[[Intramuscular min comeup time::x]] - [[Intramuscular max comeup time::y]] [[Intramuscular comeup time units::minutes]]
|IntramuscularROA_Peak=[[Intramuscular min peak time::x]] - [[Intramuscular max peak time::y]] [[Intramuscular peak time units::hours]]
|IntramuscularROA_Offset=[[Intramuscular min offset time::x]] - [[Intramuscular max offset time::y]] [[Intramuscular offset time units::hours]]
|IntramuscularROA_Aftereffects=[[Intramuscular min afterglow time::x]] - [[Intramuscular max afterglow time::y]] [[Intramuscular afterglow time units::hours]]
|IntravenousROA=false
|IntravenousROA_Collapsed=true
|IntravenousROA_Caption=
|IntravenousROA_Bioavailability=[[Intravenous min bioavailability::x]]% - [[Intravenous max bioavailability::y]]%<ref>APA formatted citation</ref>
|IntravenousROA_Light=[[Intravenous min light dose::x]] - [[Intravenous max light dose::y]] mg
|IntravenousROA_Common=[[Intravenous min common dose::x]] - [[Intravenous max common dose::y]] mg
|IntravenousROA_Strong=[[Intravenous min strong dose::x]] - [[Intravenous max strong dose::y]] mg
|IntravenousROA_Heavy=[[Intravenous heavy dose::x]] mg +
|IntravenousROA_TimelineFile=
|IntravenousROA_TimelineWidth=
|IntravenousROA_Duration=[[Intravenous min total time::x]] - [[Intravenous max total time::y]] [[Intravenous total time units::hours]]
|IntravenousROA_Onset=[[Intravenous min onset time::x]] - [[Intravenous max onset time::y]] [[Intravenous onset time units::minutes]]
|IntravenousROA_Comeup=[[Intravenous min comeup time::x]] - [[Intravenous max comeup time::y]] [[Intravenous comeup time units::minutes]]
|IntravenousROA_Peak=[[Intravenous min peak time::x]] - [[Intravenous max peak time::y]] [[Intravenous peak time units::hours]]
|IntravenousROA_Offset=[[Intravenous min offset time::x]] - [[Intravenous max offset time::y]] [[Intravenous offset time units::hours]]
|IntravenousROA_Aftereffects=[[Intravenous min afterglow time::x]] - [[Intravenous max afterglow time::y]] [[Intravenous afterglow time units::hours]]
}}
Glaucine is rarely sold on the streets and almost exclusively distributed as a legal alternative to more common psychedelics, where it is commonly used for recreational and entheogenic purposes. It was and still is a very uncommon and unheard of substance with sparing experiences on the internet.
Glaucine is rarely sold on the streets and almost exclusively distributed as a legal alternative to more common psychedelics, where it is commonly used for recreational and entheogenic purposes. It was and still is a very uncommon and unheard of substance with sparing experiences on the internet.
Line 258:
Line 35:
*'''[[Effect::Muscle relaxation]]'''
*'''[[Effect::Muscle relaxation]]'''
*'''[[Effect::Perception of bodily heaviness]]'''
*'''[[Effect::Perception of bodily heaviness]]'''
*'''[[Effect::Phsycial euphoria]]''' - It is usually felt as a warm encompassment of the body.
*'''[[Effect::Physical euphoria]]''' - It is usually felt as a warm encompassment of the body.
*'''[[Effect::Pupil dilation]]''' - Serotonergic substances are known to cause pupil dilation.
*'''[[Effect::Pupil dilation]]''' - Serotonergic substances are known to cause pupil dilation.
If applicable, a brief paragraph summary describing the visual geometry produced by the substance may be included here.
====Hallucinatory states====
If applicable, a brief summary of the substance's visual effects profile may be written here.
*'''[[Effect::Hallucinatory states1]]'''
}}
|{{effects/cognitive|
If applicable, a brief paragraph summary of the substance's cognitive effects may be included here.
You may select from a list of cognitive effects to add below [[Subjective effect index#Cognitive effects|here]].
*'''[[Effect::Cognitive effect1]]'''
*'''[[Effect::Cognitive effect2]]'''
*'''[[Effect::Cognitive effect3]]'''
}}
{{effects/auditory|
If applicable, a brief paragraph summary of the substance's auditory effects may be included here.
You may select from a list of auditory effects to add below [[Subjective effect index#Auditory effects|here]].
*'''[[Effect::Auditory effect1]]'''
*'''[[Effect::Auditory effect2]]'''
}}
{{effects/multisensory|
If applicable, a brief paragraph summary of the substance's multisensory effects may be included here.
You may select from a list of multisensory effects to add below [[Subjective effect index#Multisensory effects|here]].
*'''[[Effect::Multisensory effect1]]'''
*'''[[Effect::Multisensory effect2]]'''
}}
{{effects/transpersonal|
If applicable, a brief paragraph summary of the substance's transpersonal effects may be included here.
You may select from a list of transpersonal effects to add below [[Subjective effect index#Transpersonal effects|here]].
*'''[[Effect::Transpersonal effect1]]'''
*'''[[Effect::Transpersonal effect2]]'''
}}
}}
}}
}}
===Experience reports===
===Experience reports===
There are currently {{#ask:[[Category:SUBSTANCE]][[Category:Experience]] | format=count}} experience reports which describe the effects of this substance in our [[experience index]]. Additional experience reports can be found here:
There are currently {{#ask:[[Category:Glaucine]][[Category:Experience]] | format=count}} experience reports which describe the effects of this substance in our [[experience index]]. Additional experience reports can be found here:
*'''Lithium''': Lithium is commonly prescribed in the treatment of bipolar disorder; however, there is a large body of anecdotal evidence that suggests taking it with psychedelics can significantly increase the risk of [[psychosis]] and [[seizures]]. As a result, this combination should be '''strictly avoided.'''
*'''Lithium''': Lithium is commonly prescribed in the treatment of bipolar disorder; however, there is a large body of anecdotal evidence that suggests taking it with psychedelics can significantly increase the risk of [[psychosis]] and [[seizures]]. As a result, this combination should be '''strictly avoided.'''
*'''[[Tramadol]]''': Tramadol is well documented to lower the seizure threshold in individuals and psychedelics also has the potential to induce seizures in susceptible individuals.<ref>https://www.sciencedirect.com/science/article/pii/S0376871622003234?via%3Dihub</ref>
*'''[[Tramadol]]''': Tramadol is well documented to lower the seizure threshold in individuals and psychedelics also has the potential to induce seizures in susceptible individuals.<ref>https://www.sciencedirect.com/science/article/pii/S0376871622003234?via%3Dihub</ref>
Line 341:
Line 72:
*'''[[Stimulants]]''': (e.g. [[Amphetamine|'''''amphetamine''''']], [[Project talk:Methcathinone|'''''methcathinone''''']]): Due to a moderate inhibition of MAO-B, stimulants in combination with glaucine will cause a massive spike in blood pressure leading to hypertensive crisis as well as prolonged and more intense effects of stimulants. This combination should be '''strictly avoided.'''
*'''[[Stimulants]]''': (e.g. [[Amphetamine|'''''amphetamine''''']], [[Project talk:Methcathinone|'''''methcathinone''''']]): Due to a moderate inhibition of MAO-B, stimulants in combination with glaucine will cause a massive spike in blood pressure leading to hypertensive crisis as well as prolonged and more intense effects of stimulants. This combination should be '''strictly avoided.'''
*'''Tyramine''': Any food with a high level of tyramine should be avoided for two weeks after use. MAO-B inhibition can lead to a buildup of tyramine in the body, leading to a hypertensive crisis.
*'''Tyramine''': Any food with a high level of tyramine should be avoided for two weeks after use. MAO-B inhibition can lead to a buildup of tyramine in the body, leading to a hypertensive crisis.
It may contain incorrect information, particularly with respect to dosage, duration, subjective effects, toxicity and other risks. It may also not meet PW style and grammar standards.
Glaucine is a naturally occurring novel psychedelic substance of the aporphine class found in Glaucium Flavum.[1] Glaucine has one stereocenter, therefore it has two stereoisomers, where (S)-Glaucine is a 5-HT2Aagonist and (R)-Glaucine is a 5-HT2 positive allosteric modulator.[2] Its psychedelic effects are believed to be produced by its interaction with serotoninreceptors like most psychedelics do, but also has clinically significant interactions at D1[3] and α1[4] receptors as an antagonist, and inhibits MOA to a moderate degree.[5] Glaucine has a close relative found in Blue Lotus (Nymphaea nouchali) called apomorphine. It is both psychedelic as well as sedating, but the sedation is more similar to that of opioids than psilocybin, a generally sedating psychedelic. It is most commonly consumed orally.
WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.
DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.
Glaucine is rarely sold on the streets and almost exclusively distributed as a legal alternative to more common psychedelics, where it is commonly used for recreational and entheogenic purposes. It was and still is a very uncommon and unheard of substance with sparing experiences on the internet.
Due to its potent sedating effects as well as unknown toxicity profile, it is strongly recommended that one use proper harm reduction practices if choosing to use this substance.
Glaucine was first described in 1839 by Probst, defined as an 'acrid alkaloid, and was first isolated by Richard Fischer in 1901.[7] It has been used used for millennia, where records back to the year 131 claim it was used for aches and sores as well as abscess' in present-day Turkey.[7] In an overview study in 2007, glaucine's antitussive effectiveness was confirmed along with its potent bronchodilation effects, but lacked the respiratory depression and habit-forming use associated with opioid antitussives.[8] Today, it is sold as an antitussive medicine in Iceland and eastern European countries, as well as being used off-label for asthma.[9] It has very few written experiences online, but the earliest found is from 2009.[10]
As a result, it may contain incomplete or wrong information. You can help by expanding it.
Chemistry
Glaucine is an aporphine, meaning 'not morphine.' It is named this because despite similar structure to morphine, it is in fact not morphine. Aporphine is the parent compound of glaucine, where glaucine has methoxy groups substituted at the 1, 2, 9, and 10 positions. Glaucine has one stereocenter, meaning it has two stereoisomers. Both stereoisomers are found in nature, albeit in different plants.[11]
Glaucine is a sedative-psychedelic. The psychedelic effects perceived from glaucine are in fact from interaction of 5-HT2A receptors, but both stereoisomers of glaucine interact with the receptor differently. (S)-glaucine is an agonist of the receptor, the same action performed by psychedelics like LSD and mescaline, but (R)-glaucine is a positive allosteric modulator, meaning it boosts the signaling and activity at the receptor.[2] Its sedating effects are believed to come from its strong antagonism at α1 receptors, the same receptors that the stimulant caffeine agonizes.[4] D1 antagonism is common amongst aporphines such as apomorphine, and might be a cause of reduction in drug-seeking behaviors following administration such as seen with apomorphine.[12]
Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWikicontributors. As a result, they should be viewed with a healthy degree of skepticism.
It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.
Physical effects
Glaucine can be described as a warm and encompassing body high with an especially prominent euphoria. The body high can be described as more opiate-like than psychedelic, preferring physical euphoria over tactile sensations.
Increased respiration - Potent bronchodilation allows for a more vast airflow, though the feeling is uncomfortable and might feel like one is suffocating.
Cough suppression - Glaucine is known to be an antitussive with the same effectiveness as codeine.
Motor control loss - Strong sedation leads to a decrease in coordination and motivation to move.
Pain relief - Glaucine has been reported to reduce the signaling of pain receptors.
Sedation - Glaucine is known for its strong sedation due to α1 antagonism.
Bronchodilation This is caused by antagonism of benzothiazepine sites in the brain.
There are currently 0 experience reports which describe the effects of this substance in our experience index. Additional experience reports can be found here:
Intragastrical administration of glaucine to rats in doses of 5, 25 and 75 mg/kg bodyweight daily for 3 months did not produce any detectable harm to any organ. It has also been concluded that it is not an allergen, mutagenic, or toxic to embryos.[13]
This toxicity and harm potential section is a stub.
As a result, it may contain incomplete or even dangerously wrong information! You can help by expanding upon or correcting it. Note: Always conduct independent research and use harm reduction practices if using this substance.
Warning:Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).
Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit.
Lithium: Lithium is commonly prescribed in the treatment of bipolar disorder; however, there is a large body of anecdotal evidence that suggests taking it with psychedelics can significantly increase the risk of psychosis and seizures. As a result, this combination should be strictly avoided.
Tramadol: Tramadol is well documented to lower the seizure threshold in individuals and psychedelics also has the potential to induce seizures in susceptible individuals.[16]
Cannabis: Cannabis has a strong, volatile synergy with psychedelics. While often used to intensify or prolong psychedelic effects, the combination increases the risk of adverse psychological effects like anxiety, paranoia, panic attacks, and psychosis. Anecdotal reports often describe cannabis use as the triggering event for a bad trip or psychosis. Caution is advised.
Depressants (e.g. GHB, alprazolam, hydrocodone): While respiratory depression isn't a problem with glaucine alone, due to the nature of the drug reducing blood pressure and heart contraction force, adding depressants could dangerously amplify the effects of a depressed CNS, leading to dangerous bradycardia, low blood pressure, and asphyxiation. Caution is advised.
Stimulants: (e.g. amphetamine, methcathinone): Due to a moderate inhibition of MAO-B, stimulants in combination with glaucine will cause a massive spike in blood pressure leading to hypertensive crisis as well as prolonged and more intense effects of stimulants. This combination should be strictly avoided.
Tyramine: Any food with a high level of tyramine should be avoided for two weeks after use. MAO-B inhibition can lead to a buildup of tyramine in the body, leading to a hypertensive crisis.
